Sanja Selak, PhD
Chief Executive and Scientific Officer (CEO/CSO)
with 25+ years of research and industry experience and an educational background in molecular biology, immunology, neurophysiology and medicine. Sanja worked and studied at various international institutions, including: Faculty of Medicine, University of Calgary, Canada; Marine Biological Laboratory (MBL), Woods Hole, USA; the Neurobiology Institute Ramon y Cajal, Madrid, Spain and the Medical School, Ljubljana, Slovenia. Sanja was previously Head of Department of Serology and Immune Assays at Intercell AG (Valneva), where she led a team of 15 senior researchers and scientists, and managed various collaborative projects with pharmaceutical companies (Novartis, GSK, Merck and Sanofi) evaluating the efficacy of product candidates from early discovery to phase II clinical trials. In 2015, Sanja, as the CEO of ORIGIMM, was nominated as one of the “20 entrepreneurs that may change the world” in the inaugural edition of the Forbes magazine Austria.
Sanja’s enthusiasm about her work and her desire to find better solutions for patients within the area of dermatology, which are not only addressing symptoms but really acting on the root cause, led her to founding ORIGIMM. Having a vision of her own, when it comes to how ORIGIMM as a small biotech company should evolve and what kind of company culture she would like to foster, she is appreciating her vast network of advisors, consultants, as well as ORIGIMM employees, who are supporting her entrepreneurial spirit and think beyond the borders of their respective field. Innovation and new ideas to make things happen is the core value of her work attitude.
More about Sanja at: https://at.linkedin.com/in/sselak
Zrinka Ivezić Schönfeld, Ph.D
Consultant to CEO and Head of Clinical Development
Zrinka is senior executive with nearly 30 years of experience in the biotech & pharma industry, with an educational background in medicinal and organic chemistry. Zrinka had built and led multidisciplinary, international drug discovery and development projects, teams and departments from early research and pre-clinical stage through all phases of clinical trials as well as post-marketing studies of drugs and medical devices. She held positions as Partner & Managing Director at SILSC GmbH (Austria), Corporate Director Clinical Development at Croma-Pharma GmbH, Austria; Managing Director/VP Non-Clinical Development and Head of Clinical Sciences Pharmacology & Toxicology at Nabriva AG; (Austria, USA) and Program Director for anti-infective drug research at PLIVA Research Institute in Croatia.
At Origimm, Zrinka is primarily responsible for clinical development. Joining at the beginning of 2020 she set up clinical department organization and led the team through an intense phase of preparation for the first clinical trial investigating a therapeutic acne vaccine. Being very thorough and structured in her work, she was connecting all the dots in this highly cross-functional project. Within the management team, Zrinka is also contributing to business strategy, including market research and interactions with key opinion leaders (KOLs). With her broad experience in leadership and strategy Zrinka contributes significantly to the development of the company.
Florian Köck, MBA
Head of Finance and Business Management
a senior executive with 20+ years of experience in leading finance functions and experience in general management (administration, HR and IT). Florian previously held finance management and executive positions in the biopharmaceutical and medical device companies Kedrion International GmbH (human plasma derivatives) and Zimmer Biomet Austria GmbH (medical implants), where he was responsible for financial management and accounting, restructuring and steering subsidiary companies, HR management of employees and commercial issues.
At Origimm, Florian is responsible for company’s commercial management, internal business operations, administration and company infrastructure. Having experienced both – small and mid-sized companies as well as corporate organizations – he is contributing to development of a growing organization. With his tech-savviness and his engagement in digitalizing our workflows and processes Florian is making his contribution in innovation inside the company.
Martin Steiner, PhD, MBA
Consultant to CEO and Head of Business Development (pharmaceutical industry)
Martin, senior executive, with 25+ years of experience in the pharma and biotechnology industry with particular focus on general management, business development and funding of start-up companies (Apovia AG (Germany) and ImVisioN Therapeutics GmbH (Germany)). He obtained a PhD in Microbiology and Genetics from the University of Vienna and an MBA from the University of Michigan. Throughout his career, Martin held several CEO and consultancy positions.
At Origimm, Martin is responsible for business development activities, including interactions and negotiations with pharmaceutical company representatives; he also contributes to the development of business case scenarios and funding strategies. Having been involved as a consultant to our CEO since early 2015 he has provided his support already in the start-up phase of the company. Especially by providing the perspective of an external stakeholder in various discussions he is an asset in helping shaping business objectives.
Barbara Moisl, M.Sc.
Head of Organizational Team Development
Barbara has educational background in the organizational change management, organizational behavior and corporate governance. She obtained extensive work experience in coordinating team-work in high pressure environments, compliance with operating procedures and installing safety measures.
At ORIGIMM, Barbara is responsible for change management, team development, culture and organizational structure to best suit the company’s current and future needs in an agile environment. She is also the executive assistant to CEO and supporting various strategic development activities. By working in close collaboration with ORIGIMM’s CEO and understanding her vision, Barbara’s task is to ensure that the organization develops in alignment with that vision and future strategic goals.